Harvard Bioscience (HBIO) Cash Flow Statement

Click line-items for a historical chart and %

Net income	-2.99M
Stock compensation expense	2.6M
Depreciation	1.17M
Gain on acquisition contingencies
Gain on sales of fixed assets	0
Restructuring charges
Amortization of catalog costs	13K
Provision for allowance for doubtful accounts	59K
Amortization of intangible assets	2.1M
Amortization of deferred financing costs	72K
Deferred income taxes	455K
Decrease (increase) in accounts receivable	2.15M
Increase in inventories	735K
Increase in other receivables and other assets	-742K
Increase in trade accounts payable	-2.79M
(Decrease) increase in accrued income taxes payable	-158K
Decrease in accrued expenses	296K
Increase in deferred revenue	29K
Decrease in other liabilities	7K
Net Cash Provided By Operating Activities	3.66M
Additions to property, plant and equipment	920K
Additions to catalog costs	34K
Proceeds from sales of property, plant and equipment	0
Final payment related to Denville Scientific acquisition	0
Net cash used in investing activities	-954K
Net proceeds from issuance of debt	3M
Repayments of debt	-6.74M
Purchases of treasury stock
Net proceeds from issuance of common stock	80K
Net cash used in financing activities	-3.66M
Effect of exchange rate changes on cash	-443K
Increase in cash and cash equivalents	-1.4M
Cash and cash equivalents at the begining of period	6.74M
Cash and cash equivalents at the end of period	5.35M
Cash paid for interest	468K
Net cash paid for income taxes	725K

Entities mentioned with HBIO

View All Entities